Inside Nephrology: A Weekly Review
Nefrologia
Nephrology Updates: CKD Management and Therapeutic Advances
This week's nephrology update covers dapagliflozin's effects on bone biomarkers, finerenone combination therapies, hypoparathyroidism treatment advances, and innovative approaches to CKD management.
Bibliography
1. Effects of Dapagliflozin on the Bone of Patients with CKD on Dialysis.
Authors: Pelepenko LE, Barreto J, Martins MP, et al.
Journal: Calcified tissue international, 2026 Aug 14
PMID: 42595915
DOI: 10.1007/s00223-026-01587-7
2. Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure.
Authors: Agarwal R, Correa-Rotter R, Navaneethan SD, et al.
Journal: Hypertension (Dallas, Tex. : 1979), 2026 Sep
PMID: 42244376
DOI: 10.1161/HYPERTENSIONAHA.126.27036
3. Associations of finerenone with reduced insulin resistance in patients with type 2 diabetes and chronic kidney disease: A real-world observational study.
Authors: Zhao X, Liu B, Sun R, et al.
Journal: Journal of diabetes investigation, 2026 Sep
PMID: 42332386
DOI: 10.1111/jdi.70368
4. Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIs.
Authors: Ono T, Okada T, Takahashi N, et al.
Journal: Blood advances, 2026 Aug 25
PMID: 42275565
DOI: 10.1182/bloodadvances.2026019701
5. Sustained improvement in renal function with palopegteriparatide in adults with chronic hypoparathyroidism: 2-year results from the phase 3 PaTHway-trial.
Authors: Rejnmark L, Gosmanova EO, Khan AA, et al.
Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2026 Aug 21
PMID: 42166177
DOI: 10.1093/jbmr/zjag085
6. Obesity management for kidney TRANSPLANTation: protocol for the vanguard phase of an innovative randomised controlled trial, embedded in routine care (OK-TRANSPLANT 2).
Authors: Clemens KK, Irwin J, Chiu M, et al.
Journal: BMJ open, 2026 Aug 11
PMID: 42580835
DOI: 10.1136/bmjopen-2026-120427
7. Anthropometric characteristics at birth and growth outcome in patients with X-linked hypophosphatemia treated with oral phosphate and active vitamin D.
Authors: Przygodda S, Brieger LC, Bohlen AV, et al.
Journal: Pediatric nephrology (Berlin, Germany), 2026 Sep
PMID: 41963716
DOI: 10.1007/s00467-026-07271-0
8. Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: Long-term efficacy and safety through 5 years in the SELECT-EARLY study.
Authors: Takeuchi T, van Vollenhoven R, Ueki Y, et al.
Journal: Modern rheumatology, 2026 Aug 31
PMID: 41967478
DOI: 10.1093/mr/roag031
9. Kidney outcomes of coenzyme Q10 supplementation in patients with genetically confirmed CoQ10 nephropathy in Japan.
Authors: Nagano C, Ushijima K, Tezuka Y, et al.
Journal: Clinical and experimental nephrology, 2026 Sep
PMID: 42435122
DOI: 10.1007/s10157-026-02917-7
10. Feasibility, safety and tolerability of intradialytic creatine supplementation in hemodialysis: A double-blind, randomized, placebo-controlled pilot study.
Authors: Doorenbos CSE, van der Veen Y, Post A, et al.
Journal: PloS one, 2026
PMID: 42555603
DOI: 10.1371/journal.pone.0354883
Authors: Pelepenko LE, Barreto J, Martins MP, et al.
Journal: Calcified tissue international, 2026 Aug 14
PMID: 42595915
DOI: 10.1007/s00223-026-01587-7
2. Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure.
Authors: Agarwal R, Correa-Rotter R, Navaneethan SD, et al.
Journal: Hypertension (Dallas, Tex. : 1979), 2026 Sep
PMID: 42244376
DOI: 10.1161/HYPERTENSIONAHA.126.27036
3. Associations of finerenone with reduced insulin resistance in patients with type 2 diabetes and chronic kidney disease: A real-world observational study.
Authors: Zhao X, Liu B, Sun R, et al.
Journal: Journal of diabetes investigation, 2026 Sep
PMID: 42332386
DOI: 10.1111/jdi.70368
4. Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIs.
Authors: Ono T, Okada T, Takahashi N, et al.
Journal: Blood advances, 2026 Aug 25
PMID: 42275565
DOI: 10.1182/bloodadvances.2026019701
5. Sustained improvement in renal function with palopegteriparatide in adults with chronic hypoparathyroidism: 2-year results from the phase 3 PaTHway-trial.
Authors: Rejnmark L, Gosmanova EO, Khan AA, et al.
Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2026 Aug 21
PMID: 42166177
DOI: 10.1093/jbmr/zjag085
6. Obesity management for kidney TRANSPLANTation: protocol for the vanguard phase of an innovative randomised controlled trial, embedded in routine care (OK-TRANSPLANT 2).
Authors: Clemens KK, Irwin J, Chiu M, et al.
Journal: BMJ open, 2026 Aug 11
PMID: 42580835
DOI: 10.1136/bmjopen-2026-120427
7. Anthropometric characteristics at birth and growth outcome in patients with X-linked hypophosphatemia treated with oral phosphate and active vitamin D.
Authors: Przygodda S, Brieger LC, Bohlen AV, et al.
Journal: Pediatric nephrology (Berlin, Germany), 2026 Sep
PMID: 41963716
DOI: 10.1007/s00467-026-07271-0
8. Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: Long-term efficacy and safety through 5 years in the SELECT-EARLY study.
Authors: Takeuchi T, van Vollenhoven R, Ueki Y, et al.
Journal: Modern rheumatology, 2026 Aug 31
PMID: 41967478
DOI: 10.1093/mr/roag031
9. Kidney outcomes of coenzyme Q10 supplementation in patients with genetically confirmed CoQ10 nephropathy in Japan.
Authors: Nagano C, Ushijima K, Tezuka Y, et al.
Journal: Clinical and experimental nephrology, 2026 Sep
PMID: 42435122
DOI: 10.1007/s10157-026-02917-7
10. Feasibility, safety and tolerability of intradialytic creatine supplementation in hemodialysis: A double-blind, randomized, placebo-controlled pilot study.
Authors: Doorenbos CSE, van der Veen Y, Post A, et al.
Journal: PloS one, 2026
PMID: 42555603
DOI: 10.1371/journal.pone.0354883
